(Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Looking at stellar Q4 results, strong US commercial growth, and increasing AI adoption, here’s what we think of Palantir stock. Maintaining independence and editorial freedom is essential to our ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Abstract Title: Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling and Induces Mast Cell Apoptosis Poster Number: 541 Session Title: Novel Mechanisms of Mast Cells, Basophils and IgE ...

today announced the presentation of a trial-in-progress poster on the Company’s first-in-human clinical trial evaluating FOG-001, the first and only direct inhibitor of β-catenin TCF4 ...

The primary endpoint is objective response rate, with progression-free survival a key secondary endpoint. The study includes a pre-registration step for arm determination by the molecular tumor board.

"Also, if someone here is working from home all the time and everyone is aware, it's obviously approved, because if it was ...

The United States Embassy in Nairobi has clarified reports regarding an alleged meeting between President William Ruto and ...